TOCAGEN INC’s (NASDAQ:TOCA) lock-up period will end on Tuesday, October 10th. TOCAGEN INC had issued 8,500,000 shares in its initial public offering on April 13th. The total size of the offering was $85,000,000 based on an initial share price of $10.00. After the end of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Several equities research analysts have issued reports on TOCA shares. Stifel Nicolaus reissued a “buy” rating and set a $24.00 target price on shares of TOCAGEN INC in a research note on Tuesday, July 25th. Zacks Investment Research raised TOCAGEN INC from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st.

ILLEGAL ACTIVITY WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/tocagen-incs-toca-lock-up-period-will-end-tomorrow.html.

Shares of TOCAGEN INC (TOCA) opened at 10.44 on Monday. TOCAGEN INC has a 1-year low of $9.68 and a 1-year high of $17.95. The firm has a market cap of $206.81 million and a PE ratio of 2.13. The firm’s 50-day moving average price is $12.69 and its 200 day moving average price is $13.25.

TOCAGEN INC (NASDAQ:TOCA) last issued its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.04). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. On average, equities research analysts forecast that TOCAGEN INC will post ($2.51) EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of TOCA. New York State Common Retirement Fund purchased a new position in shares of TOCAGEN INC in the 2nd quarter worth $108,000. TD Asset Management Inc. purchased a new position in shares of TOCAGEN INC in the 2nd quarter worth $158,000. Schwab Charles Investment Management Inc. purchased a new position in shares of TOCAGEN INC in the 2nd quarter worth $165,000. California State Teachers Retirement System purchased a new position in shares of TOCAGEN INC in the 2nd quarter worth $179,000. Finally, Teachers Advisors LLC purchased a new position in shares of TOCAGEN INC in the 2nd quarter worth $181,000. 37.87% of the stock is currently owned by institutional investors and hedge funds.

TOCAGEN INC Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Stock Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related stocks with our FREE daily email newsletter.